Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
ChromaDex Corp. (NASDAQ: CDXC), transitioning to the name Niagen Bioscience, Inc. with a new Nasdaq ticker symbol NAGE, generates a steady flow of news centered on NAD+ science and healthy aging. As the self-described global authority on nicotinamide adenine dinucleotide (NAD+), the company regularly issues updates on its Niagen ingredient, Tru Niagen supplement brand, and pharmaceutical-grade Niagen IV and injection products.
News for CDXC often includes financial results and outlooks, where ChromaDex reports quarterly and annual net sales, gross margins, net income, and cash flow metrics, along with commentary on trends in Tru Niagen and Niagen ingredient sales. These releases may also discuss expectations for future revenue growth, margin performance, and planned investments in research, development, and marketing.
Investors can also expect corporate and investor relations announcements, such as participation in healthcare and growth company conferences, investor summits, and panel discussions on longevity and supplementation. These events typically feature company management presenting ChromaDex’s strategy, financial performance, and updates on its NAD+ research and product pipeline.
Another key category of news involves product and partnership developments. ChromaDex has announced the expansion of Niagen IV and related pharmaceutical-grade Niagen products across wellness clinic networks, as well as collaborations where Niagen serves as a hero ingredient in third‑party longevity supplements. The company also highlights recognition in industry lists and awards related to health products and business impact.
Finally, ChromaDex issues scientific and regulatory updates, including information about FDA designations for nicotinamide riboside in rare disease indications and progress toward regulatory milestones. For anyone tracking CDXC, or its successor symbol NAGE, this news feed offers a consolidated view of the company’s financial performance, clinical and regulatory progress, commercial expansion, and branding evolution around Niagen and NAD+ science.
ChromaDex Corp. (NASDAQ: CDXC) will participate in a virtual presentation at the Benzinga Small Cap Conference on May 13, 2021, at 11:30am ET. CEO Rob Fried will present on a panel discussing longevity science at 1:20pm ET. This conference aims to connect small-cap companies with investors. ChromaDex's presentation will be available for replay on their investor relations website. The company is known for its research in healthy aging and its flagship product, Niagen®, which supports NAD+ levels that decline with age.
ChromaDex Corp. (NASDAQ:CDXC) will announce its first-quarter financial results for 2021 on May 6, 2021, with a conference call scheduled at 4:30 p.m. ET. The results will be released after market hours on the same day. Investors can access the call via a toll-free number or through the webcast link. ChromaDex is focused on healthy aging research and is known for its NAD+ precursor, nicotinamide riboside (NR), used in its flagship product, Tru Niagen®. The company emphasizes its commitment to innovation and growth.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Fadi Karam as the new Chief Marketing Officer. Karam brings extensive experience in driving consumer businesses and direct-to-consumer operations. He previously led a brand portfolio for Nestlé Waters North America, managing over $3 billion in revenues, and was pivotal in global brand strategies. ChromaDex's CEO, Rob Fried, expressed confidence in Karam's ability to contribute to the growth of the company's flagship product, Tru Niagen®. Karam is enthusiastic about enhancing the brand's reach and impact.
ChromaDex Corp. (NASDAQ: CDXC) has initiated a research partnership with the Citrin Foundation of Singapore to investigate the effects of Niagen® nicotinamide riboside (NR) on citrin deficiency, a rare genetic disorder. Funded studies will focus on how increased NAD+ levels could impact mitochondrial function, inflammation, and liver conditions in affected patients. Lead research will be conducted at Duke-NUS Medical School, aiming to deepen understanding of both citrin deficiency and NAD+ roles in metabolic health.
ChromaDex Corp. (NASDAQ:CDXC) announced that CEO Rob Fried and CFO Kevin Farr will present at the Lytham Partners Spring 2021 Investor Conference.
The presentation is scheduled for March 31, 2021, at 10:15 a.m. ET. Investors can watch the live webcast via the company's website or directly through the provided link.
Additionally, management will engage in virtual one-on-one meetings during the event from March 30 to April 1, 2021, with arrangements managed through Lytham Partners.
ChromaDex Corp. (NASDAQ:CDXC) announced that its CEO Rob Fried and CFO Kevin Farr will present at the Zooming with LD investor conference on March 25, 2021, at 12:30 p.m. ET. The presentation will be streamed live on the company's investor relations website. Additionally, ChromaDex management will engage in one-on-one virtual meetings with institutional investors throughout the day. Interested parties can find more information and register for the event through the provided links.
ChromaDex Corp. (NASDAQ:CDXC) announced its fourth quarter and full-year 2020 financial results, reporting total net sales of $15.4 million for Q4, an 18% increase from the previous year. Tru Niagen® sales reached $12.3 million, up 21%. The company improved its gross margin to 61.0% and reduced its net loss to ($6.1 million), resulting in a loss per share of ($0.10). Full-year net sales were $59.3 million, a 28% increase, with a net loss of ($19.9 million). The company expects continued revenue growth and margin improvement in 2021.
ChromaDex Corp. (NASDAQ:CDXC) announced that its premier NAD+ booster, Tru Niagen®, will be available in 3,000 Walmart stores across the U.S. starting June 2021. The product will come in two packaging options with different serving sizes and price points, also available for online purchase with same-day delivery. ChromaDex's CEO, Rob Fried, emphasized the importance of Tru Niagen® in supporting healthy aging by increasing NAD+ levels, which decline with age and stressors. Niagen® has been validated in nine human trials and accepted by leading regulatory agencies.
ChromaDex Corp. (NASDAQ: CDXC) will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 3:50 PM ET. A webcast will be available on their investor relations page on www.chromadex.com. The company will also hold virtual meetings on March 16 and 17. ChromaDex focuses on healthy aging, specializing in nicotinamide adenine dinucleotide (NAD+) research and its precursor, nicotinamide riboside (NR), marketed as Niagen®. Their product Tru Niagen® is available through various retailers and online.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Dr. David L. Katz to its Scientific Advisory Board. Dr. Katz is a prominent figure in nutrition and chronic disease prevention, previously serving as CEO of Diet ID and founding director of Yale’s Yale-Griffin Prevention Research Center. His expertise includes innovative research methods in preventive medicine, notably 'evidence mapping'. CEO Rob Fried expressed confidence that Dr. Katz's extensive background will enhance ChromaDex's mission to explore the health benefits of NAD+ and its precursors like nicotinamide riboside (NR).
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
